Wisconsin Department of Safety and Professional Services
Division of Policy Development
4822 Madison Yards Way
PO Box 8366
Madison WI 53708-8366

Phone: 608-266-2112
Web: http://dsps.wi.gov
Email: dsps@wisconsin.gov

**Tony Evers, Governor**
**Dawn B. Crim, Secretary**

**CONTROLLED SUBSTANCES BOARD**
**VIRTUAL/TELECONFERENCE**
**Virtual, 4822 Madison Yards Way, Madison**
**Contact: Adam Barr (608) 266-2112**
**November 12, 2021**

*The following agenda describes the issues that the Board plans to consider at the meeting. At the time of the meeting, items may be removed from the agenda. Please consult the meeting minutes for a description of the actions and deliberations of the Board.*

## AGENDA

**9:30 A.M.**
**OR IMMEDIATELY FOLLOWING THE REFERRAL CRITERIA WORK GROUP MEETING**

**OPEN SESSION – CALL TO ORDER – ROLL CALL**

**A. Adoption of Agenda (1-3)**

**B. 9:30 A.M. ANNUAL HEARING WITH LAW ENFORCEMENT LEADERS, AGENCIES, AND PROSECUTORS – Discussion and Consideration (4-5)**

1) **Introduction**
   a. Overview of Executive Order (EO) 228
   b. Background on the Wisconsin Controlled Substances Board
2) **Overview of Scheduling Processes – Wisconsin Statutes § 961.11 (6-10)**
3) **Receive Testimony Discussion Regarding Drug Trends**
   a. Presentations from Special Guests
   b. Presentation from the Wisconsin State Crime Lab Bureau
   c. Testimony from the Law Enforcement Community
   d. Open Discussion

**C. Approval of Minutes September 10, 2021 (11-12)**

**D. Reminders: Conflicts of Interests, Scheduling Concerns**

**E.** Introductions, Announcements and Recognition

**F. Administrative Matters – Discussion and Consideration**

1) Department, Staff, and Board Updates
2) Board Members – Term Expiration Dates
   a. Barman, Subhadeep – 5/1/2019
   b. Bellay, Yvonne
   c. Bloom, Alan – 5/1/2020
   d. Englebert, Doug
   e. Ferguson, Kris
   f. Kallio, Peter

g. Kaske, Herbert
h. Koresch, Sandy
i. Weitekamp, John

**Revised Guidance Regarding the Designation of Gabapentin as a Monitored Prescription Drug (13-15) – *Added via Addendum***

**G. Administrative Rule Matters – Discussion and Consideration (16-27)**

1) Preliminary Rule Draft:
   a. CSB 2.78, Relating to Scheduling Crotonyl Fentanyl
   b. CSB 2.79, Relating to Scheduling Remimazolam
   c. CSB 2.81, Relating to Scheduling Brorphine
2) Pending and Possible Rulemaking Projects

**H. Prescription Drug Monitoring Program (PDMP) Update – Discussion and Consideration (28-35)**

1) WI ePDMP Operations
   a. Q3 2021 Report
   b. Recent and Upcoming Releases
   c. Status of Grant Projects:
      1. FY 2020 Harold Rogers Prescription Drug Monitoring Program
         a. Buprenorphine Naïve Alert
      2. Overdose Data Exchange Project
      3. Buprenorphine Exclusion Project
   d. Interstate Data Sharing
   e. EHR Integration Status
2) WI ePDMP Outreach

**I.** COVID-19 – Discussion and Consideration

**J. Board Member Reports – Discussion and Consideration**

1) Medical Examining Board
2) Dentistry Examining Board
3) Board of Nursing
4) Pharmacy Examining Board

**K.** Liaison Reports

**L. Report from the Referral Criteria Work Group – Discussion and Consideration**

**M.** Deliberation on Special Use Authorizations – Discussion and Consideration

**N.** Discussion and Consideration of Items Received After Preparation of the Agenda

1) Introductions, Announcements, and Recognition
2) Administrative Matters
3) Election of Officers
4) Appointment of Liaisons and Alternates
5) Delegation of Authorities
6) Informational Items
7) Division of Legal Services and Compliance (DLSC) Matters
8) Education and Examination Matters
9) Credentialing Matters

10) Practice Matters
11) Legislative and Administrative Rule Matters
12) Liaison Reports
13) Appearances from Requests Received or Renewed
14) Speaking Engagements, Travel, or Public Relations Requests, and Reports
15) Consulting with Legal Counsel

**O. Public Comments**

**CONVENE TO CLOSED SESSION to deliberate on cases following hearing (s. 19.85(1)(a), Stats.); to consider licensure or certification of individuals (s. 19.85(1)(b), Stats.); to consider individual histories or disciplinary data (s. 19.85(1)(f), Stats.); and to confer with legal counsel (s. 19.85(1)(g), Stats.).**

**P.** Deliberation on Special Use Authorizations – Discussion and Consideration

**Q.** Consulting with Legal Counsel

**RECONVENE TO OPEN SESSION IMMEDIATELY FOLLOWING CLOSED SESSION**

**R.** Vote on Items Considered or Deliberated Upon in Closed Session if Voting is Appropriate

**S.** Open Session Items Noticed Above Not Completed in the Initial Open Session

**ADJOURNMENT**

**NEXT MEETING: JANUARY 14, 2022**

**********

MEETINGS AND HEARINGS ARE OPEN TO THE PUBLIC, AND MAY BE CANCELLED WITHOUT NOTICE.

Times listed for meeting items are approximate and depend on the length of discussion and voting. All meetings are held at 4822 Madison Yards Way, Madison, Wisconsin, unless otherwise noted. To confirm a meeting or to request a complete copy of the board's agenda, please call the listed contact person. The board may also consider materials or items filed after the transmission of this notice. Times listed for the commencement of disciplinary hearings may be changed by the examiner for the convenience of the parties. Requests for interpreters for the deaf or hard of hearing, or other accommodations, are considered upon request by contacting the Affirmative Action Officer, 608-266-2112, or the Meeting Staff at 608-266-5439.

# State of Wisconsin
# Department of Safety & Professional Services

## AGENDA REQUEST FORM

| 1) Name and title of person submitting the request: | 2) Date when request submitted: |
|---|---|
| Adam Barr, Executive Director | 11/2/21 |
| | Items will be considered late if submitted after 12:00 p.m. on the deadline date which is 8 business days before the meeting |

**3) Name of Board, Committee, Council, Sections:**

Controlled Substances Board

| 4) Meeting Date: | 5) Attachments: | 6) How should the item be titled on the agenda page? |
|---|---|---|
| 11/12/21 | ☐ Yes<br>☒ No | 9:30 A.M. ANNUAL HEARING WITH LAW ENFORCEMENT LEADERS, AGENCIES, AND PROSECUTORS – Discussion and Consideration<br>1. Introduction<br>a. Overview of Executive Order (EO) 228<br>b. Background on the Wisconsin Controlled Substances Board<br>2. Overview of Scheduling Processes – Wisconsin Statutes § 961.11<br>3. Receive Testimony Discussion Regarding Drug Trends<br>a. Presentations from Special Guests<br>b. Presentation from the Wisconsin State Crime Lab Bureau<br>c. Testimony from the Law Enforcement Community<br>d. Open Discussion |

| 7) Place Item in: | 8) Is an appearance before the Board being scheduled? *(If yes, please complete Appearance Request for Non-DSPS Staff)* | 9) Name of Case Advisor(s), if required: |
|---|---|---|
| ☒ Open Session<br>☐ Closed Session | ☐ Yes<br>☐ No | |

**10) Describe the issue and action that should be addressed:**

# State of Wisconsin
# Department of Safety & Professional Services

| | |
|---|---|
| **11) Authorization** | |
| **Signature of person making this request** | **Date** |
| **Supervisor (if required)** | **Date** |
| **Executive Director signature (indicates approval to add post agenda deadline item to agenda)** | **Date** |

**Directions for including supporting documents:**

1. **This form should be attached to any documents submitted to the agenda.**
2. **Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director.**
3. **If necessary, provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a meeting.**

# CONTROLLED SUBSTANCE SCHEDULING OVERVIEW

Nilajah Hardin

Administrative Rules Coordinator, DSPS

1

## WHAT IS SCHEDULING?

- Process Completed by the Controlled Substances Board
- Drug with the potential for abuse designated as a controlled substance in WI
- Analogs of a substance can also be scheduled

2

- Legality of possessing a drug
- How a drug's distribution is penalized
- Ability of non-physician healthcare providers to prescribe

## WHAT CAN BE IMPACTED BY SCHEDULING?

3

| | |
|---|---|
| Schedule I | Heroin, PCP, LSD |
| Schedule II | Methamphetamine, Cocaine, Opiates |
| Schedule III | Barbiturates, Anabolic Steroids |
| Schedule IV | Benzodiazepines, Ephedrine, Tramadol |
| Schedule V | Pseudoephedrine |

## SCHEDULING IN WI

4


Scope Statement
Rule Draft
Economic Impact Analysis
Fiscal Estimate
Public Hearing (if required)
Final Rule Draft
Governor and Legislative Review
Adoption
Publication
PERMANENT ADMINISTRATIVE RULES PROCESS

5


Scope Statement
Rule Draft
Governor Approval
Publication
Rule Effective
Public Hearing (if required)
Legislative Review
EMERGENCY ADMINISTRATIVE RULES PROCESS

6

1 Standard Scheduling

2 Emergency Scheduling

3 Scheduling Based on Federal Action

# SCHEDULING DRUGS AS CONTROLLED SUBSTANCES

7

- "The 8 Questions"
  - Potential for abuse
  - Scientific evidence of pharmacological effect
  - Current scientific knowledge on the substance
  - History and current pattern of abuse
  - Scope, duration and significance of abuse
  - Risk to public health
  - Potential to produce psychological or physical dependence
  - Whether the substance is an immediate precursor of an already scheduled substance

# STANDARD SCHEDULING

8

## EMERGENCY SCHEDULING

- 3 Factors
  - History and current pattern of abuse for the drug
  - Scope, duration, and significance of abuse
  - Risk to public health
- Requested by a district attorney prosecuting a case
- Emergency Rules Process – drug scheduled for 1 year
- Permanent Rules Process - must be in place before emergency rule expires

9

## SCHEDULING BASED ON FEDERAL ACTION

- Affirmative Action Process
  - DEA schedules a drug and it's published in the Federal Register
  - Board must wait 30 days from DEA publication before scheduling
  - Board approves and publishes an Affirmative Action Order
  - Affirmative Action Order schedules drug into the same schedule under WI
  - Affirmative Action Order is effective upon publication until permanent rule goes into effect
  - Board then follows Permanent Rules Process

10

**VIRTUAL/TELECONFERENCE**
**CONTROLLED SUBSTANCES BOARD**
**MEETING MINUTES**
**SEPTEMBER 10, 2021**

**PRESENT:** Yvonne Bellay, Alan Bloom, Doug Englebert, Sandy Koresch, Michael Parish, Emily Zentz

**EXCUSED:** Subhadeep Barman, Kris Ferguson, Peter Kallio, Herbert Kaske, John Weitekamp

**STAFF:** Adam Barr, Executive Director; Jameson Whitney, Legal Counsel; Nilajah Hardin, Administrative Rules Coordinator; Katlin Schwartz, Bureau Assistant; Megan Glaeser, Bureau Assistant; and other DSPS Staff

*(Dr. Michael Parish served as the representative for the Medical Examining Board at this meeting.)*

*(Emily Zentz served as the representative for the Board of Nursing at this meeting.)*

## CALL TO ORDER

Doug Englebert, Chairperson, called the meeting to order at 9:32 a.m. A quorum was confirmed with six (6) members present.

## ADOPTION OF AGENDA

**MOTION:** Alan Bloom moved, seconded by Yvonne Bellay, to adopt the Agenda as published. Motion carried unanimously.

## APPROVAL OF MINUTES OF JULY 9, 2021

**MOTION:** Sandy Koresch moved, seconded by Alan Bloom, to adopt the Minutes of July 9, 2021 as published. Motion carried unanimously.

## ADMINISTRATIVE RULE MATTERS

**Preliminary Rule Draft**

### *CSB 2.80, Relating to Scheduling Oliceridine*

**MOTION:** Alan Bloom moved, seconded by Michael Parish, to approve the preliminary rule draft of CSB 2.80, relating to scheduling Oliceridine, for posting for economic impact comments and submission to the Clearinghouse. Motion carried unanimously.

**Scope Statement**

**MOTION:** Michael Parish moved, seconded by Sandy Koresch, to approve the following Scope Statements for submission to the Department of Administration and Governor's Office and for publication:

1. CSB 2.82, Relating to Scheduling Serdexmethylphenidate
2. CSB 2.83, Relating to Scheduling Ten (10) Fentanyl Related Substances
3. CSB 2.84, Relating to Scheduling Alfaxalone
4. CSB 2.85, Relating to Excluding 6-beta-Nalterxol
5. CSB 2.86, Relating to Scheduling Fospropofol
6. CSB 2.87, Relating to Scheduling Embutramide
7. CSB 2.88, Relating to Scheduling Lacosamide
8. CSB 2.89, Relating to Scheduling Perampanel
9. CSB 2.90, Relating to Transferring 1-phenylcyclohexylamine and 1-piperidinocyclohexanecarbonitrile, Immediate Precursors to Phencyclidine, Also Known as PCP

Additionally, the Board authorizes the Chairperson to approve these Scope Statements for implementation no less than 10 days after publication. If the Board is directed to hold a preliminary public hearing on these Scope Statements, the Chairperson is authorized to approve the required notices of hearing. Motion carried unanimously.

**Affirmative Action Order**

***CSB 2.91, Relating to Scheduling 4,4'-Dimethylaminorex***

**MOTION:** Yvonne Bellay moved, seconded by Sandy Koresch, to delegate authority to the Chairperson, to approve the Affirmative Action Order for CSB 2.91, relating to scheduling 4, 4'-Dimethylaminorex; absent the receipt of an objection to doing so within 30 days of the publication of the final order listing 4, 4'-Dimethylaminorex as a schedule I controlled substance in the federal register. Motion carried unanimously.

**REPORT FROM THE REFERRAL CRITERIA WORK GROUP**

**MOTION:** Yvonne Bellay moved, seconded by Michael Parish, to accept the recommendations of the Referral Criteria Work Group and refer the specified providers to the appropriate examining boards for further proceedings. Motion carried unanimously.

**ADJOURNMENT**

**MOTION:** Michael Parish moved, seconded by Yvonne Bellay, to adjourn the meeting. Motion carried unanimously.

The meeting adjourned at 10:10 a.m.

# State of Wisconsin
# Department of Safety & Professional Services

## AGENDA REQUEST FORM

| 1) Name and title of person submitting the request: | 2) Date when request submitted: |
|---|---|
| Jon Derenne, Attorney | November 8, 2021 |
| | Items will be considered late if submitted after 12:00 p.m. on the deadline date which is 8 business days before the meeting |

**3) Name of Board, Committee, Council, Sections:**

Controlled Substances Board

| 4) Meeting Date: | 5) Attachments: | 6) How should the item be titled on the agenda page? |
|---|---|---|
| November 12, 2021 | ☒ Yes<br>☐ No | Revised guidance regarding the designation of gabapentin as a monitored prescription drug |

| 7) Place Item in: | 8) Is an appearance before the Board being scheduled? *(If yes, please complete Appearance Request for Non-DSPS Staff)* | 9) Name of Case Advisor(s), if required: |
|---|---|---|
| ☐ Open Session<br>☐ Closed Session | ☐ Yes<br>☐ No | |

**10) Describe the issue and action that should be addressed:**

Review and consider update to the board's Gabapentin guidance document to reflect that dispensers are not required to report Gabapentin dispensing where the prescriber has not included their DEA number with the prescription, and may void dispensing records that do not include a prescriber DEA number.

**11) Authorization**

*Jon Derenne* November 8, 2021

**Signature of person making this request** **Date**

**Supervisor (if required)** **Date**

**Executive Director signature (indicates approval to add post agenda deadline item to agenda)** **Date**

**Directions for including supporting documents:**
1. This form should be attached to any documents submitted to the agenda.
2. Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director.
3. If necessary, provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a meeting.

**CONTROLLED SUBSTANCES BOARD**

4822 Madison Yards Way
PO Box 8366
Madison WI 53708

Email: dsps@wisconsin.gov
Voice: 608-266-2112
FAX: 608-251-3032

# GUIDANCE REGARDING THE DESIGNATION OF GABAPENTIN AS A MONITORED PRESCRIPTION DRUG

## Background Facts

Gabapentin is a prescription medication approved by the U.S. Food and Drug Administration for the treatment of neuropathic pain and epileptic disorders. In recent years, however, Gabapentin has been increasingly encountered by law enforcement, documented in national crime lab reports, reported to poison control centers, and diverted for illicit use. The Researched Abuse, Diversion and Addiction – Related Surveillance (RADARS) System indicates an increase in Gabapentin diversion. The Drug Abuse Warning Network (DAWN) indicates a rise in emergency department visit rates for Gabapentin.

The Wisconsin Controlled Substances Board (CSB) and the Prescription Drug Monitoring Program (PDMP) staff have received requests by health care practitioners and law enforcement to have Gabapentin included in the PDMP. Prescribers have indicated it is beneficial to be aware of a patient having a prescription for Gabapentin prior to prescribing an opioid because, when combined with opioids, there is an increased risk of respiratory depression and opioid-related mortality increases significantly. Gabapentin is sought after for illicit use due to its potentiating opioid effect.

## Action Taken

In response to the facts above, the CSB has adopted Clearinghouse Rule 20-080 relating to designating Gabapentin as a prescription drug having a substantial potential for abuse, and therefore a monitored prescription drug pursuant to Wis. Stat. § 961.385 (1) (ag). Gabapentin is now listed in Wis. Admin. Code § CSB 4.03 (2) as a monitored prescription drug.

## Gabapentin Has Not Been Scheduled as a Controlled Substance

Gabapentin has been designated as a monitored prescription drug, not a controlled substance. A DEA registration number is not required for a practitioner to prescribe Gabapentin, nor is a DEA registration number required for a dispenser to fill a prescription for Gabapentin.

## Practical Impact for Many Prescribers and Dispensers of Gabapentin

Because Gabapentin has been designated a monitored prescription drug, a practitioner now must review a patient's prescription drug history as required by Wis. Admin. Code § CSB 4.105 prior to prescribing Gabapentin. Additionally, dispensers must report into the PDMP as required under Wis. Admin. Code § CSB 4.05 when dispensing Gabapentin.

## Exemptions Where the Lack of a DEA Registration Number Causes a Dispensing Reporting Error or Prevents Practitioner Access to the PDMP

A DEA registration number is currently required information for all submissions to the PDMP. Reporting of Gabapentin without a valid prescriber or pharmacy DEA registration number will trigger a submission error and the record will not be accepted by the PDMP. As a result, a dispenser will be excused from

their duties to report Gabapentin dispensing information, and may void the dispensing record, where one of the following is true:

- The dispenser does not have a DEA registration number.
- The dispenser is attempting to report Gabapentin dispensing data where the prescribing practitioner does not have a DEA number.
- The dispenser is attempting to report Gabapentin dispensing data where the prescribing practitioner has not provided their DEA number with the prescription order.

To emphasize the third bullet point above, dispensers are not obligated to correct Gabapentin dispensing records where the prescriber's DEA number has been omitted from the prescription order. These Gabapentin dispensing records missing a prescriber DEA number may be voided.

Similarly, a DEA registration number is required for a practitioner to access the PDMP system. Because of this, a practitioner who does not have a DEA registration number is exempt from the general requirement to review a patient's prescription drug history report prior to prescribing Gabapentin.

Updated instructions for revising or voiding erroneous submissions of Gabapentin dispensing with missing DEA information is available in the Data Submitter Guide.

# State of Wisconsin
# Department of Safety & Professional Services
## AGENDA REQUEST FORM

| 1) Name and title of person submitting the request: | 2) Date when request submitted: |
|---|---|
| **Nilajah Hardin, Administrative Rules Coordinator** | **11/02/21**<br>Items will be considered late if submitted after 12:00 p.m. on the deadline date which is 8 business days before the meeting |

**3) Name of Board, Committee, Council, Sections:**

Controlled Substances Board

| 4) Meeting Date: | 5) Attachments: | 6) How should the item be titled on the agenda page? |
|---|---|---|
| **11/12/21** | ☒ Yes<br>☐ No | **Administrative Rule Matters – Discussion and Consideration**<br>1. **Preliminary Rule Draft:**<br>a. **CSB 2.78, Relating to Scheduling Crotonyl Fentanyl**<br>b. **CSB 2.79, Relating to Scheduling Remimazolam**<br>c. **CSB 2.81, Relating to Scheduling Brorphine**<br>2. **Pending or Possible Rulemaking Projects** |

| 7) Place Item in: | 8) Is an appearance before the Board being scheduled? *(If yes, please complete **Appearance Request** for Non-DSPS Staff)* | 9) Name of Case Advisor(s), if required: |
|---|---|---|
| ☒ Open Session<br>☐ Closed Session | ☐ Yes<br>☒ No | **N/A** |

**10) Describe the issue and action that should be addressed:**

Attachments:
Preliminary Rule Drafts – CSB 2.78, 2.79, 2.81
Rule Projects Chart

Copies of all current Board Rule Projects Can be Viewed Here: https://dsps.wi.gov/Pages/RulesStatutes/PendingRules.aspx

**11) Authorization**

Nilajah D. Hardin — 11/02/21

**Signature of person making this request** — **Date**

**Supervisor (if required)** — **Date**

**Executive Director signature (indicates approval to add post agenda deadline item to agenda)** **Date**

**Directions for including supporting documents:**
1. **This form should be attached to any documents submitted to the agenda.**
2. **Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director.**
3. **If necessary, provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a meeting.**

STATE OF WISCONSIN
CONTROLLED SUBSTANCES BOARD

| | | |
|---|---|---|
| IN THE MATTER OF RULE-MAKING PROCEEDINGS BEFORE THE CONTROLLED SUBSTANCES BOARD | : | PROPOSED ORDER OF THE CONTROLLED SUBSTANCES BOARD ADOPTING RULES (CLEARINGHOUSE RULE ) |

PROPOSED ORDER

An order of the Controlled Substances Board to create CSB 2.78 relating to scheduling Crotonyl Fentanyl.

Analysis prepared by the Department of Safety and Professional Services.

ANALYSIS

**Statutes interpreted:** s. 961.16, Stats.

**Statutory authority:** s. 961.11 (1) and (4), Stats.

**Explanation of agency authority:**
Section 961.11 (1), Stats. provides that "[t]he controlled substances board shall administer this subchapter and may add substances to or delete or reschedule all substances listed in the schedules in ss. 961.14, 961.16, 961.18, 961.20 and 961.22 pursuant to the rule-making procedures of ch. 227."

Section 961.11(4), Stats. provides that "[i]f a substance is designated, rescheduled or deleted as a controlled substance under federal law and notice thereof is given to the controlled substances board, the board by affirmative action shall similarly treat the substance under this chapter after the expiration of 30 days from the date of publication in the federal register of a final order designating the substance as a controlled substance or rescheduling or deleting the substance or from the date of issuance of an order of temporary scheduling under 21 USC 811 (h), unless within that 30−day period, the board or an interested party objects to the treatment of the substance. If no objection is made, the board shall promulgate, without making the determinations or findings required by subs. (1), (1m), (1r) and (2) or s. 961.13, 961.15, 961.17, 961.19 or 961.21, a final rule, for which notice of proposed rulemaking is omitted, designating, rescheduling, temporarily scheduling or deleting the substance. If an objection is made the board shall publish notice of receipt of the objection and the reasons for objection and afford all interested parties an opportunity to be heard. At the conclusion of the hearing, the board shall make a determination with respect to the treatment of the substance as provided in subs. (1), (1m), (1r) and (2) and shall publish its decision, which shall be final unless altered by statute. Upon publication of an objection to the treatment by the board, action by the board under this chapter is stayed until the board promulgates a rule under sub. (2)."

**Related statute or rule:** s. 961.16, Stats.

**Summary of, and comparison with, existing or proposed federal regulation:**
On October 2, 2020, the Department of Justice, Drug Enforcement Administration published its final rule in the Federal Register listing Crotonyl Fentanyl into schedule I of the federal Controlled Substances Act. The scheduling action was effective October 2, 2020.

**Plain language analysis:**
This rule schedules Crotonyl Fentanyl as a Schedule I controlled substance.

The Controlled Substances Board did not receive an objection to similarly treat Crotonyl Fentanyl as a Schedule I controlled substance under ch. 961, Stats. within 30 days of the date of publication in the Federal Register of the final order designating Crotonyl Fentanyl as a controlled substance.

Pursuant to s. 961.11 (4), Stats., the Controlled Substances Board took affirmative action to similarly treat Crotonyl Fentanyl under ch. 961, Stats. by creating the following:

961.14 (2) (nd) 9m. Crotonyl Fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide).

The Affirmative Action order, dated November 13, 2020, took effect on November 23, 2020 to allow for publication in the Administrative Register and expires upon promulgation of a final rule.

**Summary of public comments received on statement of scope and a description of how and to what extent those comments and feedback were taken into account in drafting the proposed rule:** N/A

**Comparison with rules in adjacent states:**
**Illinois**: Illinois has not scheduled Crotonyl Fentanyl as a controlled substance.

**Iowa**: Iowa has not scheduled Crotonyl Fentanyl as a controlled substance.

**Michigan**: Michigan has not scheduled Crotonyl Fentanyl as a controlled substance.

**Minnesota:** Minnesota has not scheduled Crotonyl Fentanyl as a controlled substance.

**Summary of factual data and analytical methodologies:**
The methodology was to schedule Crotonyl Fentanyl to conform with the federal Controlled Substances Act.

**Analysis and supporting documents used to determine effect on small business or in preparation of economic impact analysis:**
The rule schedules Crotonyl Fentanyl as a Schedule I controlled substance which will not have any effect on small business.

**Fiscal Estimate:**
The proposed rules will be posted for a period of 14 days to solicit public comment on economic impact, including how the proposed rules may affect businesses, local government units, and individuals.

**Effect on small business**:
These proposed rules do not have an economic impact on small businesses, as defined in s. 227.114 (1), Stats. The Department's Regulatory Review Coordinator may be contacted by email at Daniel.Hereth@wisconsin.gov, or by calling (608) 267-2435.

**Agency contact person**:
Nilajah Hardin, Administrative Rules Coordinator, Department of Safety and Professional Services, Division of Policy Development, 4822 Madison Yards Way, P.O. Box 8366, Madison, Wisconsin 53708; telephone 608-267-7139; email at DSPSAdminRules@wisconsin.gov.

**Place where comments are to be submitted and deadline for submission**:
Comments may be submitted to Nilajah Hardin, Administrative Rules Coordinator, Department of Safety and Professional Services, Division of Policy Development, 4822 Madison Yards Way, Madison, WI 53708-8366, or by email to DSPSAdminRules@wisconsin.gov. Comments must be received by (date) to be included in the record of rulemaking proceedings.

---

TEXT OF RULE

SECTION 1. CSB 2.78 is created to read:

**CSB 2.78 Scheduling of Crotonyl Fentanyl.** Section 961.14 (2) (nd) 9m, Stats., is created to read:

961.14 (2) (nd) 9m. Crotonyl Fentanyl ((E)-N-(1-phenethylpiperidin-4-yl)-N-phenylbut-2-enamide).

SECTION 2. EFFECTIVE DATE. The rules adopted in this order shall take effect on the first day of the month following publication in the Wisconsin Administrative Register, pursuant to s. 227.22 (2) (intro.), Stats.

---

(END OF TEXT OF RULE)

---

STATE OF WISCONSIN
CONTROLLED SUBSTANCES BOARD

| | | |
|---|---|---|
| IN THE MATTER OF RULE-MAKING PROCEEDINGS BEFORE THE CONTROLLED SUBSTANCES BOARD | : | PROPOSED ORDER OF THE CONTROLLED SUBSTANCES BOARD ADOPTING RULES (CLEARINGHOUSE RULE ) |

PROPOSED ORDER

An order of the Controlled Substances Board to create CSB 2.79 relating to scheduling Remimazolam.

Analysis prepared by the Department of Safety and Professional Services.

ANALYSIS

**Statutes interpreted:** s. 961.16, Stats.

**Statutory authority:** s. 961.11 (1) and (4), Stats.

**Explanation of agency authority:**
Section 961.11 (1), Stats. provides that "[t]he controlled substances board shall administer this subchapter and may add substances to or delete or reschedule all substances listed in the schedules in ss. 961.14, 961.16, 961.18, 961.20 and 961.22 pursuant to the rule-making procedures of ch. 227."

Section 961.11(4), Stats. provides that "[i]f a substance is designated, rescheduled or deleted as a controlled substance under federal law and notice thereof is given to the controlled substances board, the board by affirmative action shall similarly treat the substance under this chapter after the expiration of 30 days from the date of publication in the federal register of a final order designating the substance as a controlled substance or rescheduling or deleting the substance or from the date of issuance of an order of temporary scheduling under 21 USC 811 (h), unless within that 30−day period, the board or an interested party objects to the treatment of the substance. If no objection is made, the board shall promulgate, without making the determinations or findings required by subs. (1), (1m), (1r) and (2) or s. 961.13, 961.15, 961.17, 961.19 or 961.21, a final rule, for which notice of proposed rulemaking is omitted, designating, rescheduling, temporarily scheduling or deleting the substance. If an objection is made the board shall publish notice of receipt of the objection and the reasons for objection and afford all interested parties an opportunity to be heard. At the conclusion of the hearing, the board shall make a determination with respect to the treatment of the substance as provided in subs. (1), (1m), (1r) and (2) and shall publish its decision, which shall be final unless altered by statute. Upon publication of an objection to the treatment by the board, action by the board under this chapter is stayed until the board promulgates a rule under sub. (2)."

**Related statute or rule:** s. 961.16, Stats.

**Summary of, and comparison with, existing or proposed federal regulation:**
On October 6, 2020, the Department of Justice, Drug Enforcement Administration published its final rule in the Federal Register listing Remimazolam into schedule IV of the federal Controlled Substances Act. The scheduling action was effective October 6, 2020.

**Plain language analysis:**
This rule schedules Remimazolam as a Schedule IV controlled substance.

The Controlled Substances Board did not receive an objection to similarly treat Remimazolam as a Schedule IV controlled substance under ch. 961, Stats. within 30 days of the date of publication in the Federal Register of the final order designating Remimazolam as a controlled substance.

Pursuant to s. 961.11 (4), Stats., the Controlled Substances Board took affirmative action to similarly treat Remimazolam under ch. 961, Stats. by creating the following:

961.20 (2) (mo) Remimazolam.

The Affirmative Action order, dated November 13, 2020, took effect on November 23, 2020 to allow for publication in the Administrative Register and expires upon promulgation of a final rule.

**Summary of public comments received on statement of scope and a description of how and to what extent those comments and feedback were taken into account in drafting the proposed rule:** N/A

**Comparison with rules in adjacent states:**
**Illinois**: Illinois has not scheduled Remimazolam as a controlled substance.

**Iowa**: Iowa temporarily designated Remimazolam as a Schedule IV controlled substance, via their temporary amendment process, effective May 12, 2021 (ARC 5541C - Iowa Administrative Rules).

**Michigan**: Michigan has not scheduled Remimazolam as a controlled substance.

**Minnesota:** Minnesota has not scheduled Remimazolam as a controlled substance.

**Summary of factual data and analytical methodologies:**
The methodology was to schedule Remimazolam to conform with the federal Controlled Substances Act.

**Analysis and supporting documents used to determine effect on small business or in preparation of economic impact analysis:**
The rule schedules Remimazolam as a Schedule IV controlled substance which will not have any effect on small business.

**Fiscal Estimate:**
The proposed rules will be posted for a period of 14 days to solicit public comment on economic impact, including how the proposed rules may affect businesses, local government units, and individuals.

**Effect on small business**:
These proposed rules do not have an economic impact on small businesses, as defined in s. 227.114 (1), Stats. The Department's Regulatory Review Coordinator may be contacted by email at Daniel.Hereth@wisconsin.gov, or by calling (608) 267-2435.

**Agency contact person**:
Nilajah Hardin, Administrative Rules Coordinator, Department of Safety and Professional Services, Division of Policy Development, 4822 Madison Yards Way, P.O. Box 8366, Madison, Wisconsin 53708; telephone 608-267-7139; email at DSPSAdminRules@wisconsin.gov.

**Place where comments are to be submitted and deadline for submission**:
Comments may be submitted to Nilajah Hardin, Administrative Rules Coordinator, Department of Safety and Professional Services, Division of Policy Development, 4822 Madison Yards Way, Madison, WI 53708-8366, or by email to DSPSAdminRules@wisconsin.gov. Comments must be received by (date) to be included in the record of rulemaking proceedings.

---

TEXT OF RULE

SECTION 1. CSB 2.79 is created to read:

**CSB 2.79 Scheduling of Remimazolam.** Section 961.20 (2) (mo), Stats., is created to read:

961.20 (2) (mo) Remimazolam.

SECTION 2. EFFECTIVE DATE. The rules adopted in this order shall take effect on the first day of the month following publication in the Wisconsin Administrative Register, pursuant to s. 227.22 (2) (intro.), Stats.

---

(END OF TEXT OF RULE)

---

STATE OF WISCONSIN
CONTROLLED SUBSTANCES BOARD

| | | |
|---|---|---|
| IN THE MATTER OF RULE-MAKING PROCEEDINGS BEFORE THE CONTROLLED SUBSTANCES BOARD | : | PROPOSED ORDER OF THE CONTROLLED SUBSTANCES BOARD ADOPTING RULES (CLEARINGHOUSE RULE ) |

PROPOSED ORDER

An order of the Controlled Substances Board to create CSB 2.81 relating to scheduling Brorphine.

Analysis prepared by the Department of Safety and Professional Services.

ANALYSIS

**Statutes interpreted:** s. 961.16, Stats.

**Statutory authority:** s. 961.11 (1) and (4), Stats.

**Explanation of agency authority:**
Section 961.11 (1), Stats. provides that "[t]he controlled substances board shall administer this subchapter and may add substances to or delete or reschedule all substances listed in the schedules in ss. 961.14, 961.16, 961.18, 961.20 and 961.22 pursuant to the rule-making procedures of ch. 227."

Section 961.11(4), Stats. provides that "[i]f a substance is designated, rescheduled or deleted as a controlled substance under federal law and notice thereof is given to the controlled substances board, the board by affirmative action shall similarly treat the substance under this chapter after the expiration of 30 days from the date of publication in the federal register of a final order designating the substance as a controlled substance or rescheduling or deleting the substance or from the date of issuance of an order of temporary scheduling under 21 USC 811 (h), unless within that 30−day period, the board or an interested party objects to the treatment of the substance. If no objection is made, the board shall promulgate, without making the determinations or findings required by subs. (1), (1m), (1r) and (2) or s. 961.13, 961.15, 961.17, 961.19 or 961.21, a final rule, for which notice of proposed rulemaking is omitted, designating, rescheduling, temporarily scheduling or deleting the substance. If an objection is made the board shall publish notice of receipt of the objection and the reasons for objection and afford all interested parties an opportunity to be heard. At the conclusion of the hearing, the board shall make a determination with respect to the treatment of the substance as provided in subs. (1), (1m), (1r) and (2) and shall publish its decision, which shall be final unless altered by statute. Upon publication of an objection to the treatment by the board, action by the board under this chapter is stayed until the board promulgates a rule under sub. (2)."

**Related statute or rule:** s. 961.16, Stats.

**Summary of, and comparison with, existing or proposed federal regulation:**
On March 1, 2021, the Department of Justice, Drug Enforcement Administration published its final rule in the Federal Register listing Brorphine into schedule I of the federal Controlled Substances Act. The scheduling action was effective March 1, 2021.

**Plain language analysis:**
This rule schedules Brorphine as a Schedule I controlled substance.

The Controlled Substances Board did not receive an objection to similarly treat Brorphine as a Schedule I controlled substance under ch. 961, Stats. within 30 days of the date of publication in the Federal Register of the final order designating Brorphine as a controlled substance.

Pursuant to s. 961.11 (4), Stats., the Controlled Substances Board took affirmative action to similarly treat Brorphine under ch. 961, Stats. by creating the following:

961.14 (2) (et) Brorphine.

The Affirmative Action order, dated April 16, 2021, took effect on May 3, 2021 to allow for publication in the Administrative Register and expires upon promulgation of a final rule.

**Summary of public comments received on statement of scope and a description of how and to what extent those comments and feedback were taken into account in drafting the proposed rule:** N/A

**Comparison with rules in adjacent states:**
**Illinois**: Illinois has not scheduled Brorphine as a controlled substance.

**Iowa**: Iowa has not scheduled Brorphine as a controlled substance.

**Michigan**: Michigan has not scheduled Brorphine as a controlled substance.

**Minnesota:** Minnesota has not scheduled Brorphine as a controlled substance.

**Summary of factual data and analytical methodologies:**
The methodology was to schedule Brorphine to conform with the federal Controlled Substances Act.

**Analysis and supporting documents used to determine effect on small business or in preparation of economic impact analysis:**
The rule schedules Brorphine as a Schedule I controlled substance which will not have any effect on small business.

**Fiscal Estimate:**
The proposed rules will be posted for a period of 14 days to solicit public comment on economic impact, including how the proposed rules may affect businesses, local government units, and individuals.

**Effect on small business**:
These proposed rules do not have an economic impact on small businesses, as defined in s. 227.114 (1), Stats. The Department's Regulatory Review Coordinator may be contacted by email at Daniel.Hereth@wisconsin.gov, or by calling (608) 267-2435.

**Agency contact person**:
Nilajah Hardin, Administrative Rules Coordinator, Department of Safety and Professional Services, Division of Policy Development, 4822 Madison Yards Way, P.O. Box 8366, Madison, Wisconsin 53708; telephone 608-267-7139; email at DSPSAdminRules@wisconsin.gov.

**Place where comments are to be submitted and deadline for submission**:
Comments may be submitted to Nilajah Hardin, Administrative Rules Coordinator, Department of Safety and Professional Services, Division of Policy Development, 4822 Madison Yards Way, Madison, WI 53708-8366, or by email to DSPSAdminRules@wisconsin.gov. Comments must be received by (date) to be included in the record of rulemaking proceedings.

---

TEXT OF RULE

SECTION 1. CSB 2.81 is created to read:

**CSB 2.81 Scheduling of Brorphine.** 961.14 (2) (et), Stats., is created to read:

961.14 (2) (et) Brorphine.

SECTION 2. EFFECTIVE DATE. The rules adopted in this order shall take effect on the first day of the month following publication in the Wisconsin Administrative Register, pursuant to s. 227.22 (2) (intro.), Stats.

---

(END OF TEXT OF RULE)

---

**Controlled Substances Board**
**Rule Projects (updated 11/01/21)**

| CH Rule Number | Scope Number | Scope Expiration Date | Code Chapter Affected | Relating Clause | Stage of Rule Process | Next Step |
|---|---|---|---|---|---|---|
| Not Assigned Yet | 070-21 | 02/29/2024 | CSB 2.78 | Scheduling Crotonyl Fentanyl | Preliminary Rule Draft Presented at 11/12/21 Meeting | Post for EIA Comments and Submission to Clearinghouse |
| Not Assigned Yet | 071-21 | 02/29/2024 | CSB 2.79 | Scheduling Remimazolam | Preliminary Rule Draft Presented at 11/12/21 Meeting | Post for EIA Comments and Submission to Clearinghouse |
| Not Assigned Yet | 061-21 | 12/28/2023 | CSB 2.80 | Scheduling Oliceridine | Submission to Clearinghouse | Board Review of Final Rule Draft and Legislative Report at 01/14/22 Meeting |
| Not Assigned Yet | 072-21 | 02/29/2024 | CSB 2.81 | Scheduling Brorphine | Preliminary Rule Draft Presented at 11/12/21 Meeting | Post for EIA Comments and Submission to Clearinghouse |
| Not Assigned Yet | 088-21 | 04/18/2024 | CSB 2.82 | Scheduling Serdexmethylphenidate | Scope Published in Administrative Register on 10/18/21 | Scope Approval for Implementation |
| Not Assigned Yet | 089-21 | 04/18/2024 | CSB 2.83 | Scheduling 10 Fentanyl Related Substances | Scope Published in Administrative Register on 10/18/21 | Scope Approval for Implementation |
| Not Assigned Yet | 090-21 | 04/18/2024 | CSB 2.84 | Scheduling Alfaxalone | Scope Published in Administrative Register on 10/18/21 | Scope Approval for Implementation |
| Not Assigned Yet | 091-21 | 04/18/2024 | CSB 2.85 | Excluding 6-beta-Naltrexol | Scope Published in Administrative Register on 10/18/21 | Scope Approval for Implementation |
| Not Assigned Yet | 092-21 | 04/18/2024 | CSB 2.86 | Scheduling Fospropofol | Scope Published in Administrative Register on 10/18/21 | Scope Approval for Implementation |
| Not Assigned Yet | 093-21 | 04/18/2024 | CSB 2.87 | Scheduling Embutramide | Scope Published in Administrative Register on 10/18/21 | Scope Approval for Implementation |
| Not Assigned Yet | 094-21 | 04/18/2024 | CSB 2.88 | Scheduling Lacosamide | Scope Published in Administrative Register on 10/18/21 | Scope Approval for Implementation |

**Controlled Substances Board**
**Rule Projects (updated 11/01/21)**

| CH Rule Number | Scope Number | Scope Expiration Date | Code Chapter Affected | Relating Clause | Stage of Rule Process | Next Step |
|---|---|---|---|---|---|---|
| Not Assigned Yet | 095-21 | 04/18/2024 | CSB 2.89 | Scheduling Perampanel | Scope Published in Administrative Register on 10/18/21 | Scope Approval for Implementation |
| Not Assigned Yet | 096-21 | 04/18/2024 | CSB 2.90 | Transferring 1-phenylcyclohexylamine and 1-piperidinocyclohexanecarbonitrile, Immediate Precursors to Phencyclidine, Also Known as PCP | Scope Published in Administrative Register on 10/18/21 | Scope Approval for Implementation |
| Not Assigned Yet | Not Assigned Yet | Not Determined Yet | CSB 2.91 | Scheduling 4,4'-Dimethylaminorex | Affirmative Action Order Published in Administrative Register on 09/27/21 | Scope Statement for Board Review at 01/14/22 Meeting |

# State of Wisconsin
# Department of Safety & Professional Services

## AGENDA REQUEST FORM

| 1) Name and title of person submitting the request: | 2) Date when request submitted: |
|---|---|
| Marjorie Liu<br>**Program Lead, PDMP** | 11/02/2021<br>Items will be considered late if submitted after 12:00 p.m. on the deadline date which is 8 business days before the meeting |

**3) Name of Board, Committee, Council, Sections:**

Controlled Substances Board

| 4) Meeting Date: | 5) Attachments: | 6) How should the item be titled on the agenda page? |
|---|---|---|
| 11/12/2021 | ☒ Yes<br>☐ No | Prescription Drug Monitoring Program (PDMP) Updates – Discussion and Consideration |

| 7) Place Item in: | 8) Is an appearance before the Board being scheduled? *(If yes, please complete **Appearance Request** for Non-DSPS Staff)* | 9) Name of Case Advisor(s), if required: |
|---|---|---|
| ☒ Open Session<br>☐ Closed Session | ☐ Yes<br>☒ No | |

**10) Describe the issue and action that should be addressed:**

1. WI ePDMP Operations
    a. Q3 2021 Report
    b. Recent and Upcoming Releases
    c. Status of Grant Projects:
        i. FY 2020 Harold Rogers Prescription Drug Monitoring Program
            - Buprenorphine Naïve Alert
        ii. Overdose Data Exchange Project
        iii. Buprenorphine Exclusion Project
    d. Interstate Data Sharing
    e. EHR Integration Status
2. WI ePDMP Outreach

**11) Authorization**

Marjorie Liu — 11/2/2021

Signature of person making this request — Date

Supervisor (if required) — Date

Executive Director signature (indicates approval to add post agenda deadline item to agenda) — Date

**Directions for including supporting documents:**
1. This form should be attached to any documents submitted to the agenda.
2. Post Agenda Deadline items must be authorized by a Supervisor and the Policy Development Executive Director.
3. If necessary, provide original documents needing Board Chairperson signature to the Bureau Assistant prior to the start of a meeting.

# 2019-2021 Development and Release Summary

*Updated 10.31.2021*

| Release Date | Description |
|---|---|
| **Pending** | |
| **HRG 2020 Component 1**<br>**Release date TBD** | Security Enhancements<br>• Two-Factor Authentication<br>• Compromised Email Address Check<br>Patient Report and other User Experience Updates |
| **R25**<br>**November 2021** | Maintenance Updates<br>• Adjustments to triggering Annual Terms and Conditions prompt<br>• Enhanced EHR Integration Testing capabilities<br>• Chatbot display changes |
| **Completed** | |
| **R24**<br>**August 2021** | Text Updates<br>• Gabapentin related text changes to the Submitter Error Email.<br>Security-Related Enhancements |
| **R23**<br>**July 2021** | Text Updates<br>• Gabapentin related text changes to the Submitter Error Email. |
| **R22**<br>**July 2021** | Pharmacy-Related Enhancements<br>• Missing DEA Number Error Process Updates<br>Administrative-Related Enhancements |
| **R21**<br>**May 2021** | New Design Enhancements<br>• Proactive MC/HCP linkage renewals<br>• Search enhancements<br>Administrative-Related Enhancements<br>Additional administrator tools |
| **R20**<br>**March 2021** | WI DOJ-Medical College of Wisconsin DataShare Project<br>• Automatically send data extracts to DOJ-MCW<br>• Automatically receive data extracts from DOJ-MCW<br>Administrative-Related Enhancements<br>• Additional improvements to query process<br>• Additional administrator tools |
| **R19**<br>**September 2020** | New Design Enhancements<br>• Enhanced MME calculation process<br>• Ability to set map display defaults<br>Administrative-Related Enhancements |

| | |
|---|---|
| | • Improvements to query approval process<br>Search Engine Optimization<br>Updates to non-user facing parts of the PDMP to optimize search engine results |
| **R18**<br>**July 2020** | New Design Enhancements<br>• Updated layout and design of Patient Report including alerts and dispensing details, based on user feedback<br>• Opioid naïve alert<br>Additional EHR Enhancements<br>• Multi-state default settings<br>Prescriber Metrics Notifications<br>Proactive notice to prescribers to review metrics, based on time and/or prescribing thresholds |
| **R17.1**<br>**April 2020** | Pharmacy-Related Enhancements<br>• Display of Date Sold, if provided in the submission<br>• ASAP file processing improvements |
| **R17**<br>**March 2020** | Pharmacy-Related Enhancements<br>• Improvements to workflow for error corrections/void<br>• Display of Date Sold, if provided in the submission<br>New Design Enhancements<br>• Better access to history of recent Patient Reports for Delegates<br>• Additional data element on overdose alerts entered by law enforcement to capture administration of Naloxone<br>• MME calculator<br>Additional EHR Enhancements<br>• Expanded patient search from within EHR<br>• Expanded navigation from within EHR |
| **R16**<br>**Dec 2019** | Patients Panel Improvements<br>• Additional data fields EHR Enhancements<br>• Additional state query from within the EHR, as contractually allowable (initially RxCheck states only)<br>• Delegate Management ability from within EHR<br>• Ability of Delegates to identify as licensed/unlicensed |
| **Minor Interim Release**<br>**Oct 2019** | Patient matching updates<br>• Specific improvement for linking patients based on nicknames |
| **R15.1**<br>**Sept 2019** | Performance-Related Enhancements<br>• Performance improvements for Medical Coordinator role |

| | |
|---|---|
| **R15**<br>**Aug 2019** | User Management Enhancements<br>• Annual acceptance of Term and Conditions of the WI ePDMP<br>• Renewal process for Medical Coordinator access to metrics<br>• Periodic review of linked delegates |
| **R14**<br>**April 2019** | RxCheck<br>• Technical tasks to establish connection to RxCheck interstate data sharing hub |
| **R12 and R13**<br>**March 2019** | Data Quality Software Stability Work<br>• Technical tasks to simplify workflows and improve identification/resolution of workflow issues |
| **R11**<br>**February 2019** | DHS Extract<br>• Addition of patient geocode latitude and longitude<br>Quality Assurance and Support Items |

## Buprenorphine Naïve Alert

Consideration and advice of the Board are needed for Buprenorphine Naïve Alert that was proposed by practitioners in pain management during the BJA HR2020 focus group sessions.

### Background

Buprenorphine Naïve Alert was planned in 2019 along with "Opioid Naïve Alert" to be released in 2020. Buprenorphine Naïve Alert in the end was not implemented per the advice of Dr. Westlake (then the PDMP liaison) after a discussion with two other doctors in pain management and addiction medicine. The main reason was to reduce noises that concurrent Opioid and Buprenorphine alert might create.

New circumstances have arisen as Buprenorphine for opioid use disorder will be excluded from certain calculations including the Opioid Naive Alert (scheduled to be released in Spring 2022). The focus group Buprenorphine Naive Alert proposal would only include Buprenorphine prescribed for Opioid use disorder compared to the 2019 enhancement plan that would have included any Buprenorphine. See the comparison between the two proposals below:

- 2019 Enhancement: Any Buprenorphine prescribed since January 1, 2013
- 2021 Focus Group: Buprenorphine prescribed for Opioid use disorder in the past 5 years



## Interstate Data Sharing

| RxCheck/EHR | PMPi |
|---|---|
| **In Progress** | |
| **MO** | |
| **Connected** | |
| IL, MD, NE, PA, UT, WA, | AZ, CO, DE, FL, HI, IA, ID, IN, KS, ME, MI, MN, MT, NC, ND, NM, NV, NY, PR, SC, SD, TN, WV, Military Health System |

## WI ePDMP EHR Integration Services Summary

*Current as of 10.31.2021*

| Pending Health Systems and EHR Platforms |
|---|
| Advanced Pain Management (In Development) |
| Advent Health (In Development) |
| Advent Health - Cerner |
| Athena (In Discussion) |
| DrFirst (In Development) |
| Marshfield EHR System Change (In Discussion/Contracting) |
| Prairie Clinic (In Discussion) |
| Wisconsin Statewide Health Information Network (Converting to new EHR Platform) |
| M Health Fairview (In Discussion/Contracting) |
| Bluestone Physician Services (In Discussion/Contracting) |
| Clean Slate (In Discussion) |
| **Connected Health Systems (approx. 50% of monthly patient queries)** |
| Ascension Wisconsin |
| Aspirus Health Care |
| Aurora Health Care |
| Children's Hospital of Wisconsin |
| Froedtert & the Medical College of Wisconsin |
| GHC of South Central Wisconsin |
| Gundersen Health System |
| HealthPartners |

| |
|---|
| HSHS / Prevea Health |
| Marshfield Clinic |
| Mayo Clinic |
| Mercy Health |
| Monroe Clinic |
| NOVO Health Technology Group |
| ProHealth Care |
| SSM Health |
| Thedacare |
| UnityPoint |
| UW Health |
| Wisconsin Statewide Health Information Network |

## 2021 WI PDMP Outreach Calendar

| MONTH | EVENT | DESCRIPTION | DATES | NOTES |
|---|---|---|---|---|
| January | | | | |
| February | | | | |
| March | | | | |
| April | Rx Drug Abuse & Heroin Summit | Panelist, PDMP & Patient Privacy | 4/6/2021 | Virtual Conference |
| | Overdose Fatality Review (OFR) State Advisory Group | DSPS Representative | 4/29/2021 | Quarterly Meeting. Inter-agency advisory group for OFR local sites. |
| May | Law Enforcement Outreach | Self-Paced PDMP Training -- Lake Delton & Fox Point Police Department | | Voice-over & Animated Power Point Slides |
| June | PDMP Roundtable | Advocate Aurora (Kenosha) | 6/9/2021 | |
| July | North Region PDMP Webinar | Annual TTAC/BJA Regional Conference for 12 PDMPs located in the PDMP TTAC North region | 7/1/2021 | Virtual |
| | Law Enforcement PDMP participation promotion initiative | Collaborative Initiative between DSPS, DOJ & North Central HIDTA | 7/8/2021 | Monthly Meeting |
| August | Tribal Nation PDMP Participation | MOU with St. Croix under development | | |
| September | Great Lake Inter-Tribal Council Board Meeting | Great Lake Inter-Tribal Council Board Meeting | 9/13/2021 | |
| October | PDMP Rountable | Family Health Center of Marshfield, Inc. | 10/19/2021 | |
| | PMP InterConnect Steering Committee Meeting | Meeting organized by National Association of Boards of Pharmacy (NABP) | 10/6-10/7/2021 | In-Person or Hybrid meeting in Northbrook, IL |
| November | 2021 COSSAP National Forum | Comprehensive Opioid, Stimulant, and Substance Abuse Program (COSSAP) Annual Conference | TBA (Initially 9/28-9/30/2021) | Virtual conference. Required participation for BJA grantees |
| December | | | | |